Shibani Malhotra

Nomura’s Shibani Malhotra maintained a Buy rating on Endo International plc - Ordinary Shares (NASDAQ: ENDP), with a price target of $80. Overreaction To Minor Update Malhotra believes the selloff in the stock, following a “minor update” by the company, was an overreaction...

Nomura’s Shibani Malhotra downgraded Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from Buy to Neutral, while slashing the price target from $175 to $60. She commented, “We have lost conviction in Valeant.” The company has announced a larger reduction in its 2016 than was...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) collapsed to a new 52-week low of $88.50 on Wednesday before slightly rebounding but have still lost more than 50 percent over the past three months.. Citron Research published what it considered to be a "smoking gun" report on Wednesday which...

In a report published Wednesday, Sterne Agee analyst Shibani Malhotra commented that Actavis plc's (NYSE: ACT) growth profile remains "underappreciated" and investors should buy shares following recent weakness related to a pending offering. Malhotra wrote that the company's Investor Day...

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Supreme Court win Tuesday represents a small gain for the company, according to an analyst. Teva changed hands recently at $58.44, up 1.2 percent. Justices ruled that an appeals court wrongly invalidated a patent on Teva's Copaxone...

Sterne Agee upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) Friday from Neutral to Buy and raised its price target from $56 to $65. Analyst Shibani Malhotra noted that upgrade came amid “2015 guidance that has now put a floor on Teva’s ex-copaxone earnings, increased...

Sterne Agee commented on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) Tuesday with analyst Shibani Malhotra suggesting that “accounting concerns may be overdone.” Malhotra noted, “Post last month’s disclosure by Salix management that inventory levels for key products were...

Sterne Agee issued a report on Endo International PLC (NASDAQ: ENDP) Tuesday and suggested that "recent weakness" created a "good entry point." The firm maintained a Buy rating and $75 price target. Analysts Shibani Malhotra and Austin Nelson noted that "Endo has agreed...

In a report published Wednesday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $272.00 price target on Actavis plc (NYSE: ACT). In the report, Sterne Agee noted, “Although Actavis failed to garner support at today's FDA AdCom for the product, we do not see this as being very...

Following a meeting with Actavis’ management, analysts at Sterne Agee increased the earnings estimates and price target on Actavis plc (NYSE: ACT). Analyst Shibani Malhotra stated,”we raise the price target from $255 to $272 and remain buyers of Actavis on a fundamental basis....

In a report published Friday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $162.00 price target on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). In the report, Sterne Agee noted, “2Q14 results were lower than expected due to continued inventory shifts as Salix integrates Santarus,...

In a report published Monday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $185.00 price target on Allergan (NYSE: AGN). In the report, Sterne Agee noted, “We held a call with Allergan's CEO David Pyott, that left us even more convinced that management's actions are motivated by...

In a report published Friday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), and raised the price target from $126.00 to $130.00. In the report, Sterne Agee noted, “The outcome of today's FDA Panel on mu opioid antagonists, although not...